Efficacy of biological agents in metastatic triple-negative breast cancer.
about
Apatinib for molecular targeted therapy in tumorPredictive biomarkers for triple negative breast cancer treated with platinum-based chemotherapy.Canadian Cancer Trials Group IND197: a phase II study of foretinib in patients with estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2-negative recurrent or metastatic breast cancer.Xanthatin, a novel potent inhibitor of VEGFR2 signaling, inhibits angiogenesis and tumor growth in breast cancer cells.Lapatinib increases motility of triple-negative breast cancer cells by decreasing miRNA-7 and inducing Raf-1/MAPK-dependent interleukin-6.Targeting FOSB with a cationic antimicrobial peptide, TP4, for treatment of triple-negative breast cancer.Triple-negative breast cancer: investigating potential molecular therapeutic target.BRCA1-like profile is not significantly associated with survival benefit of non-myeloablative intensified chemotherapy in the GAIN randomized controlled trial.A network meta-analysis on the efficacy of targeted agents in combination with chemotherapy for treatment of advanced/metastatic triple-negative breast cancer.Targeting chaperonin containing TCP1 (CCT) as a molecular therapeutic for small cell lung cancer.Pattern of metastatic spread and subcategories of breast cancer.The efficacy and safety of bevacizumab combined with chemotherapy in treatment of HER2-negative metastatic breast cancer: a meta-analysis based on published phase III trials.Metastatic and triple-negative breast cancer: challenges and treatment optionsPrecision medicine based on tumorigenic signaling pathways for triple-negative breast cancer
P2860
Q26775828-45FD4BFF-0F3C-41EC-BB16-DAA91E87EBE9Q33441772-8E75B1D6-984D-4D17-82E6-1699EFB78C1BQ35999644-B2F7B030-C201-4848-8D7F-E6777856FE2FQ36261367-6C919BAC-9726-479D-AA47-F865765DC733Q36545926-51C855E8-BAFB-4FF2-A082-0A132CFDB81EQ37457870-8A2C81DB-3D0F-4AF6-B3EB-F6FFE05DB00CQ38259322-0B20AC8A-028D-42EB-B06A-E9C66AA0F7A5Q38617840-5430C863-E86F-402C-92C0-DBC6D5B0B7A5Q41709095-5898B268-7039-4534-95B9-F15497ED3E1EQ47107751-A6B8D4E4-8F5C-4826-80A8-7F3065016AFEQ50550387-8E425F39-6263-4A96-8C78-287AABA636EFQ54310257-4C806AD1-0735-4AA2-860B-F9E96AC01BD8Q57105258-C197EA35-CC50-4823-84C1-81206D909BC3Q57105411-74ECCEBB-5EC4-48BF-9AEF-68E00BCE1C58
P2860
Efficacy of biological agents in metastatic triple-negative breast cancer.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Efficacy of biological agents in metastatic triple-negative breast cancer.
@en
type
label
Efficacy of biological agents in metastatic triple-negative breast cancer.
@en
prefLabel
Efficacy of biological agents in metastatic triple-negative breast cancer.
@en
P2093
P1476
Efficacy of biological agents in metastatic triple-negative breast cancer.
@en
P2093
Anna Moretti
Annalisa Bramati
Elena Galfrascoli
Gabriella Farina
Maria Chiara Dazzani
Nicla Maria La Verde
Paola Sburlati
Serena Girelli
Sheila Piva
Valter Torri
P304
P356
10.1016/J.CTRV.2014.01.003
P577
2014-02-04T00:00:00Z